Dhan Chand/LinkedIn
Nov 19, 2024, 20:44
Dhan Chand: Expanding treatment options through innovative iNKT cell therapy combinations
Dhan Chand, Vice President of Research at Agenus, shared a post on LinkedIn:
“Novel cell therapy combinations can deepen and extend the reach of immunotherapy.
At SITC2024 visit Poster 753 where Martyna Popis and Nils Rudqvist present AgenT-797, MiNK Therapeutics novel allogeneic iNKT cell therapy.
New data shows how AgenT-797 enhances checkpoint inhibitors and bispecific engagers to drive curative responses in challenging solid tumors.
This work represents an important step forward in expanding treatment options for cancer patients through innovative iNKT cell therapy combinations.
More posts featuring Dhan Chand.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 6, 2025, 17:52
Sep 6, 2025, 17:48
Sep 6, 2025, 17:39
Sep 6, 2025, 17:28
Sep 6, 2025, 15:55
Sep 6, 2025, 15:54